Steven Arkin

4.4k total citations
53 papers, 2.5k citations indexed

About

Steven Arkin is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Steven Arkin has authored 53 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 15 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Steven Arkin's work include Hemophilia Treatment and Research (30 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Blood Coagulation and Thrombosis Mechanisms (10 papers). Steven Arkin is often cited by papers focused on Hemophilia Treatment and Research (30 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Blood Coagulation and Thrombosis Mechanisms (10 papers). Steven Arkin collaborates with scholars based in United States, Italy and France. Steven Arkin's co-authors include Jeanne M. Lusher, Richard S. Schwartz, Charles F. Abildgaard, Jörge E. Cortes, Carlo Gambacorti‐Passerini, H. Jean Khoury, Tim H. Brümmendorf, Anna Turkina, Hagop M. Kantarjian and Sucharita J. Mistry and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Steven Arkin

51 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Arkin United States	24	1.7k	693	621	301	258	53	2.5k
Paula Marlton Australia	27	1.2k 0.7×	789 1.1×	1.1k 1.7×	988 3.3×	803 3.1×	137	3.1k
Toshiko Motoji Japan	26	1.5k 0.9×	700 1.0×	915 1.5×	578 1.9×	399 1.5×	121	2.6k
Hugh D Carr-Smith United Kingdom	10	912 0.5×	364 0.5×	1.1k 1.8×	363 1.2×	141 0.5×	14	1.6k
Alejandro Martı́n Spain	25	909 0.5×	533 0.8×	845 1.4×	1.4k 4.6×	465 1.8×	128	2.8k
Cristina Papayannidis Italy	26	1.4k 0.8×	508 0.7×	1.0k 1.6×	882 2.9×	207 0.8×	160	2.7k
Edgar Jost Germany	23	551 0.3×	318 0.5×	1.0k 1.6×	392 1.3×	314 1.2×	100	1.8k
John C. Byrd United States	19	1.7k 1.0×	1.4k 2.0×	1.5k 2.4×	720 2.4×	540 2.1×	81	3.7k
G. Tertian France	17	578 0.3×	684 1.0×	468 0.8×	364 1.2×	527 2.0×	48	2.0k
Alessandro Gozzetti Italy	28	1.7k 0.9×	928 1.3×	1.1k 1.7×	1.0k 3.4×	512 2.0×	147	2.8k
Edward C. Bradley United States	18	650 0.4×	755 1.1×	762 1.2×	585 1.9×	418 1.6×	32	2.0k

Countries citing papers authored by Steven Arkin

Since Specialization

Citations

This map shows the geographic impact of Steven Arkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Arkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Arkin more than expected).

Fields of papers citing papers by Steven Arkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Arkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Arkin. The network helps show where Steven Arkin may publish in the future.

Co-authorship network of co-authors of Steven Arkin

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Arkin. A scholar is included among the top collaborators of Steven Arkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Arkin. Steven Arkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arkin, Steven, et al.. (2023). Practical and Statistical Considerations for the Long Term Follow‐Up of Gene Therapy Trial Participants. Clinical Pharmacology & Therapeutics. 115(1). 139–146. 9 indexed citations

Hauber, Brett, et al.. (2023). Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development. Journal of Patient Experience. 10. 672723143–672723143. 2 indexed citations

Jani, Darshana, et al.. (2023). Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab. The AAPS Journal. 25(5). 84–84.

Coyne, Karin S., Brooke M. Currie, Michael U. Callaghan, et al.. (2022). Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies. European Journal Of Haematology. 109(3). 226–237. 2 indexed citations

Mahlangu, Johnny, Daniel R Malan, Silva Zupančić Šalek, et al.. (2022). A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British Journal of Haematology. 200(2). 229–239. 28 indexed citations

Visweshwar, Nathan, Thomas J. Harrington, Andrew D. Leavitt, et al.. (2021). Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 138(Supplement 1). 564–564. 16 indexed citations

Leavitt, Andrew D., Barbara A. Konkle, Kimo C. Stine, et al.. (2020). Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 136(Supplement 1). 12–12. 21 indexed citations

Gruppo, Ralph A., Daniel R Malan, J. Kapocsi, et al.. (2018). Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis. 16(10). 1984–1993. 17 indexed citations

Hua, Fei, et al.. (2017). Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L). Journal of Thrombosis and Haemostasis. 15(5). 931–937. 23 indexed citations

10.

Shankar, Ganesh M., Steven Arkin, Viswanath Devanarayan, et al.. (2014). Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations. The AAPS Journal. 16(4). 658–673. 236 indexed citations

11.

Recht, Michael, László Nemes, Michał Matysiak, et al.. (2009). Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII. Haemophilia. 15(4). 869–880. 67 indexed citations

12.

Yamamoto, Kazuhiko, Jason A. Aglipay, Juan Sironi, et al.. (2008). Upregulated ATM Gene Expression and Activated DNA Crosslink-Induced Damage Response Checkpoint in Fanconi Anemia: Implications for Carcinogenesis. Molecular Medicine. 14(3-4). 167–174. 9 indexed citations

13.

Kraut, Eric H., et al.. (2007). Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia. 13(5). 508–517. 23 indexed citations

14.

Lusher, Jeanne M., C F Abildgaard, Steven Arkin, et al.. (2004). Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. Journal of Thrombosis and Haemostasis. 2(4). 574–583. 61 indexed citations

15.

Jason, Janine, Lynn A. Sleeper, Sharyne Donfield, et al.. (1995). Evidence for a Shift from a Type I Lymphocyte Pattern with HIV Disease Progression. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 10(4). 471–476. 13 indexed citations

16.

Jason, Janine, Bruce L. Evatt, John Murphy, et al.. (1994). Immune and serologic profiles of HIV‐infected and noninfected hemophilic children and adolescents. American Journal of Hematology. 46(1). 29–35. 16 indexed citations

17.

Kroner, Barbara L., Steven Arkin, MW Hilgartner, et al.. (1993). Loss of high‐responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi‐center hemophilia cohort study. American Journal of Hematology. 42(4). 375–379. 99 indexed citations

18.

Lusher, Jeanne M., Steven Arkin, Charles F. Abildgaard, & Richard S. Schwartz. (1993). Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors. New England Journal of Medicine. 328(7). 453–459. 373 indexed citations

19.

Schwartz, Richard S., Charles F. Abildgaard, Louis M. Aledort, et al.. (1990). Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. New England Journal of Medicine. 323(26). 1800–1805. 185 indexed citations

20.

Arkin, Steven, et al.. (1989). An intrinsic progenitor defect in Diamond‐Blackfan anaemia. British Journal of Haematology. 73(1). 112–120. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact